Ketamine, Neuroplasticity, and Brain-Derived Neurotrophic Factor

Ketamine neuroplasticity and brain-derived neurotrophic factor (BDNF) are the two mechanisms most often cited to explain why low-dose ketamine can ease depression symptoms within hours instead of the weeks typically needed for SSRIs and other monoaminergic antidepressants. Neuroplasticity is the brain's capacity to reorganize synaptic connections and build new neural circuits in response to experience or injury. BDNF is a neurotrophin protein that regulates the growth, strengthening, and survival of those synaptic connections. Research over the past two decades links chronic stress and major depressive disorder (MDD) to synaptic atrophy in the prefrontal cortex and hippocampus, and ketamine's ability to rapidly reverse that atrophy by triggering BDNF release is considered central to its fast-acting antidepressant effect.

The Neuroplasticity Hypothesis of Depression

Synaptic Deficit in the Prefrontal Cortex and Hippocampus

Postmortem studies of people with major depressive disorder show reduced dendritic spine density and lower expression of synaptic proteins in the prefrontal cortex (PFC), the brain region responsible for executive function and emotional regulation (Duman et al., 2016). Preclinical models of chronic stress show a similar pattern of dendritic retraction and spine loss in the PFC and hippocampus. This synaptic deficit model reframes depression, in part, as a disorder of impaired connectivity between neurons rather than solely a shortage of serotonin or other monoamines. For a closer look at the cellular signaling involved, see our guide to neuroplasticity mechanisms.

Why the Prefrontal Cortex Is Especially Vulnerable

The medial PFC governs top-down control over limbic structures involved in mood and fear. When chronic stress damages synaptic connections in this region, the resulting loss of control is thought to contribute to rumination, anhedonia, and impaired decision-making, all common symptoms of depression. Reversing this synaptic loss, rather than simply raising neurotransmitter levels, is the target of ketamine's rapid mechanism of action.

How Ketamine Triggers Synaptogenesis

NMDA Receptor Blockade and the Glutamate Burst

The N-methyl-D-aspartate (NMDA) receptor is a glutamate receptor subtype central to normal excitatory signaling and synaptic plasticity throughout the brain. Ketamine is a non-competitive NMDA receptor antagonist, and at low, sub-anesthetic doses it preferentially blocks NMDA receptors located on GABAergic interneurons, cells that are tonically active and normally keep neighboring pyramidal neurons in check. Blocking these interneurons disinhibits pyramidal neurons in the PFC, producing a short burst of glutamate release. That glutamate activates postsynaptic AMPA receptors, setting off the signaling cascade responsible for ketamine's neuroplastic effects.

BDNF Release and TrkB Activation

Brain-derived neurotrophic factor (BDNF) is a neurotrophin protein that regulates the growth, maturation, and survival of synapses and is considered a master regulator of synaptic plasticity. Increased AMPA receptor signaling triggers BDNF release from presynaptic and postsynaptic compartments. According to Li et al. (2010), publishing in Science, a single sub-anesthetic dose of ketamine rapidly increased BDNF protein levels in the prefrontal cortex and hippocampus of rodents. BDNF then binds tropomyosin receptor kinase B (TrkB) on postsynaptic neurons. Studies using BDNF Val66Met knock-in mice, which carry a mutation that impairs activity-dependent BDNF secretion, found these animals fail to show an antidepressant-like response to ketamine (Liu et al., 2012), indicating BDNF release is required for the effect rather than merely correlated with it.

mTOR Signaling and New Synaptic Proteins

TrkB activation switches on several intracellular pathways, the best characterized being the mechanistic target of rapamycin (mTOR) pathway, which coordinates the protein synthesis needed for synapse formation. Li et al. (2010) found that ketamine rapidly activates mTOR signaling in the PFC, increasing synthesis of synaptic proteins such as PSD-95, the AMPA receptor subunit GluA1, and synapsin I. Blocking mTOR with rapamycin eliminates both the synapse-building and antidepressant effects of ketamine in rodent models, evidence that this pathway, not NMDA blockade alone, produces the therapeutic effect. Ketamine's molecular profile as an NMDA receptor antagonist is documented in the National Center for Biotechnology Information's PubChem compound summary for ketamine.

Structural and Functional Evidence for Synaptic Rebuilding

Spine Formation Observed in Real Time

Using two-photon laser scanning microscopy in living animals, Moda-Sava et al. (2019), publishing in Science, showed that ketamine reverses stress-induced dendritic spine loss in the PFC within 24 hours. Their data indicated that ketamine largely restores previously lost synaptic connections rather than building entirely new ones, and that this spine restoration was required for the antidepressant behavioral effects to persist. Electrophysiological recordings support this structural finding: ketamine increases the frequency and amplitude of excitatory postsynaptic currents in PFC pyramidal neurons, and this functional strengthening tracks closely with new spine growth and behavioral improvement in animal models.

Human Neuroimaging and Peripheral BDNF

Human studies provide a translational bridge to this preclinical data. Abdallah et al. (2017) reported that ketamine increases global brain connectivity in the PFC on functional MRI, and that the degree of connectivity change correlates with antidepressant response. Separately, clinical studies measuring peripheral BDNF levels in blood have produced mixed results, but a subset report that ketamine responders show larger increases in peripheral BDNF than non-responders (Haile et al., 2014). Researchers are still working out how well peripheral BDNF reflects what is happening centrally in the brain; for more on how clinicians try to predict who will respond to treatment, see our overview of biomarkers of ketamine response.

What This Mechanism Means for Treatment

According to the National Institute of Mental Health, depression involves changes in brain structure and function that go beyond neurotransmitter levels alone, which is part of why researchers have moved toward mechanisms like synaptic plasticity to explain both the disorder and its treatments (NIMH, Depression). This framework has directed drug development toward compounds that selectively enhance AMPA signaling, stimulate BDNF-TrkB activity, or activate mTOR signaling without ketamine's full dissociative profile. It has also shaped clinical practice: because ketamine opens a window of heightened synaptic plasticity, many providers pair treatment with psychotherapy or structured cognitive work during that window to help consolidate adaptive changes rather than relying on the drug alone. Our guide to combination therapy protocols covers how this pairing is approached in practice.